Review Article
Intravitreal Devices for the Treatment of Vitreous Inflammation
Table 4
Comparison of intravitreal implants for the treatment of noninfectious uveitis [
40].
| | 0.59 mg fluocinolone acetonide (FA) implant | 0.7 mg dexamethasone (DEX) implant |
| Administration | Operating room | Officebased | Matrix | Non-biodegradable | Biodegradable | Duration of effect | 30 months | 6 months | Improvement of >15 letters (% eyes) | 21% by week 34 | 38% by week 26 | Rescue medications (% eyes) | 25.4% by week 34 | 22% by week 26 | Glaucoma surgery (% eyes) | 30.6% by month 24 | 0.5% by month 6 | Cataract surgery (% eyes) | 89.4% by month 24 | 4% by month 6 |
|
|